- Northwest Biotherapeutics
-
NorthWest Biotherapeutics (NWBT) Type Public (Nasdaq: [1]) Industry Pharmaceuticals Headquarters Bothell, Washington Products DCVax Brain
DCVax Prostate
See more complete products listing.Website www.nwbio.com Northwest Biotherapeutics is an American pharmaceutical company that focuses on developing immunotherapies against different types of cancer.
Contents
Mission
NWBT's stated goals stress product quality and purity, innovation, and efficient production.[2]
Technology
The DCVax technology upon which NWBT's therapies rely involves injecting cancer patients with dendritic cells, which contain high levels of the same antigens found in tumor cells. The immune system, alerted by these antigens, attacks the cancer as well as the injected cells.
Products
DCVax Brain is set to be distributed at select centers in Switzerland by September 2007.[1] DCVax Prostate has also been approved by the FDA for trials.[3]
Footnotes and references
- ^ "First brain cancer vaccine approved in Switzerland". Yahoo! News. 2007-07-09. http://news.yahoo.com/s/afp/20070709/hl_afp/britainswitzerlandus_070709081252;_ylt=ArGCEiDyCusWMNb.7GuF5_wE1vAI. Retrieved 2007-07-09.[dead link]
External links
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.